

Destroying Cancer at the Speed of Light®

Energy Activated Small Molecules for Targeted Cancer Therapy

Non-Muscle-Invasive Bladder Cancer (NMIBC) Market

- 63,652 new U.S. bladder cancer cases annually
- **$1.8 billion annual revenue opportunity**
- Five organizations expected to share market: **≈$375 million in potential annual revenue each**

Study II Update

- **Study complete** (87 patients complete)
- Clinical data for Health Canada New Drug Submission **(NDS)** and FDA New Drug Application **(NDA)** (1Q2027)
- FDA/Health Canada marketing approval for **NMIBC**
- Pursuing licensing agreements for bladder cancer technologies

Pipeline


- Complete **IV Rutherrin® GLP toxicology**
- Commence **Phase 0/I/II adaptive clinical studies** in Glioblastoma Multiforme, Non-Small Cell Lung Cancer, Muscle-Invasive Bladder Cancer, Pancreatic and Colorectal cancers (2027)
- Complete **Topical Ruvidar® GLP toxicology** for Herpes Simplex Virus cold sores (HSV-1)
- Commence **Phase I/II/III adaptive clinical study** for HSV-1

Indication	Pre-clinical	GLP Tox	Phase 1	Phase 2	NDS / NDA Decision
Non-Muscle-Invasive Bladder Cancer					2027

Investor Relations

Matthew Perraton | 866-843-5273 ext 229 | mperraton@theralase.com
theralase.com | theralase.com/invest | **TSXV: TLT | OTCQB: TLTFF**

FDA and Non-FDA Approved Drugs



1) Steinberg G et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol. 2000 Mar;163(3):761-7. Erratum in: J Urol. 2008 Jan;179(1):386 **(Not used clinically)**
2) Balar, A.V., et al., Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol, 2021. 22(7): p. 919-930. **(Not used clinically)**
3) Press Release –enGene Announces Updated Interim Results From LEGEND Pivotal Cohort – May 7, 2026 **(3 years of treatment)**
4) TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer – February 23, 2026 **(1.5 years of treatment)**
5) Rose KM et al., Systematic Review and Meta-Analysis of Response Rates in BCG-unresponsive Non–Muscle-Invasive Bladder Cancer: A Consensus Statement From the International Bladder Cancer Group. Société Internationale d'Urologie Journal. 2022
6) Press Release - Theralase Provides Bladder Cancer Clinical Study Update – October 26, 2026 **(1 day treatment)**
7) FDA Press Announcement - FDA Approves First Gene Therapy for the Treatment of High-Risk, Non-Muscle-Invasive Bladder Cancer **(1 year of treatment)**
8) Press Release – ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer – April 22, 2024 **(2 years of treatment)**
9) Press Release - U.S. FDA approval of INLEXZO™ - September 9, 2025 **(2 years of treatment) (25% SAE occurrence rate)**
10) Wei Zhao et al. A New Bliss Independence Model to Analyze Drug Combination Data. SLAS Discovery. Volume 19, Issue 5. 2014. Pages 817-821
11) CG Oncology Announces Publication of Phase 3 BOND-003 Cohort C Results in the Lancet Oncology– July 27, 2026 **(Only applicable to patients who exhibit retinoblastoma negative defect)**